OKUR

OnKure Therapeutics, Inc.
  • Healthcare
  • Biotechnology
  • $126M market cap
Forecast run · Sep 14, 2026Upside rank 498 of 3,136

Model Signal

ForecastQ Daily Probabilities
55.7%
30.0%
42.3%

Analyst Consensus

Recommendation2.00/5 Buy
Last price$3.10
Price target$14.00
Implied move+351.6%
Analysts2

ForecastQ Portfolios

OKUR is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

ForecastQ

Quantitative stocks signals powered by AI


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.